MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update
2023年7月28日 - 9:30PM
MiNK Therapeutics (Nasdaq: INKT), a clinical-stage
biopharmaceutical company specializing in the discovery,
development and commercialization of allogeneic, off-the-shelf,
invariant natural killer T (iNKT) cell therapies to treat cancer
and other immune-mediated diseases, today announced that the
company will release its second quarter 2023 financial results via
press release before the market opens on Thursday, Aug. 10.
In addition, MiNK Chief Executive Officer and President Jennifer
Buell, Ph.D., will participate in and provide an update on the
progress of the company’s portfolio at the following upcoming
investor conference:
- BTIG Virtual Biotechnology
Conference 2023 – A fireside chat will be held virtually
on Tuesday, Aug. 8, at 11:30 a.m. ET.
A replay of the fireside chat from the BTIG conference will be
accessible on the company’s website at
https://investor.minktherapeutics.com/events-and-presentations
following the event.
About MiNK Therapeutics
MiNK Therapeutics is a clinical-stage biopharmaceutical company
pioneering the discovery, development and commercialization of
allogeneic invariant natural killer T (iNKT) cell therapies to
treat cancer and other immune-mediated diseases. MiNK is advancing
a pipeline of both native and next-generation engineered iNKT
programs, with a platform designed to facilitate scalable and
reproducible manufacturing for off-the-shelf delivery. The company
is headquartered in New York, New York. For more information, visit
https://minktherapeutics.com/. Follow us on Twitter @MiNK_iNKT.
Investor Contact
Zack Armen
917-362-1370
investors@minktherapeutics.com
Media Contact
Alexa Buffa
781-674-4428
communications@minktherapeutics.com
MiNK Therapeutics (NASDAQ:INKT)
過去 株価チャート
から 4 2024 まで 5 2024
MiNK Therapeutics (NASDAQ:INKT)
過去 株価チャート
から 5 2023 まで 5 2024